Navigation Links
BIKAM and Dalton Medicinal Chemistry Expand and Renew Research Agreement
Date:10/29/2009

BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics.

Boston, MA and Toronto, ON (PRWEB) October 29, 2009 -- BIKAM, pioneers in the discovery and development of potential therapeutic agents for the treatment of degenerative eye diseases and ocular disorders and Dalton Medicinal Chemistry have jointly announced a renewal of their exclusive worldwide collaboration and agreement to discover and develop new ophthalmology therapeutics.

Dalton Medicinal Chemistry will continue to utilize their proprietary insights to advance several novel classes of compounds against selected BIKAM targets. BIKAM will advance these agents with their growing cutting edge battery of biological assays and delivery methodologies.

David Garvey, VP, Chemistry at BIKAM commented: “For the past 18 months we have had a very productive relationship with the Dalton Medicinal Chemistry team”.

Judd Berman, Co-founder of Dalton Medicinal Chemistry, said: “It’s been exceptionally exciting to work with the talented scientists at BIKAM to advance these important programs towards clinical development and beyond. We are delighted to have the opportunity to further contribute to these pioneering programs.”

About BIKAM
BIKAM, Inc. is a biopharmaceutical company focused on the development of novel therapeutics for the treatment of degenerative eye diseases and disorders. BIKAM is building a portfolio of product candidates based on patented technologies that were identified at the University of Florida, Gainesville. BIKAM investors include HealthCare Ventures, CHL Medical Partners and Fidelity Biosciences.

About Dalton Medicinal Chemistry & Dalton Pharma Services
Dalton Medicinal Chemistry Incorporated (DMC) was established to offer select partners medicinal chemistry capabilities in design and synthesis of new chemical entities.
DMC focuses on quality, creativity and speed in the delivery of innovative, high quality medicinal chemistry capabilities for the identification of new chemical entities which advance our clients' drug discovery programs. Our contributions to clinical development candidate selection include SAR elucidation, design and synthesis of focused compound arrays, hit to lead, lead optimization and generation of intellectual property. DMC has full access to Dalton Pharma Services (DPS) and its world class synthetic laboratories equipped with the latest technology in modern synthetic chemistry, structural determination and purity assessment.

Dalton Pharma Services is a Health Canada approved contract pharmaceutical manufacturer that supplies chemistry, analytical and formulation development services to biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. Dalton provides cGMP manufacturing of solid dosage forms and sterile filling services to its customers at any stage of the regulatory process (Phase I, II, III or commercial). In its state of the art cGMP facilities, Dalton produces active pharmaceutical ingredients at the gram or kilogram scale. Dalton conducts sterile fills to produce batches of finished drug product in vials or syringes, either aseptically filled or terminally sterilized, under fully validated conditions. In addition, Dalton’s analytical chemistry laboratory offers method development, validation and ICH stability programs to its clients.

Contact:
BIKAM, Inc.
David Garvey
dgarvey (at) bikampharma (dot) com

Dalton Medicinal Chemistry
Peter Pekos
416-661-2102
www.dalton.com

###

Read the full story at http://www.prweb.com/releases/Dalton_BIKAM/Medicinal_Chemistry/prweb3131644.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Dalton Pharma Services Adds Formulation Development Services
2. Dalton Pharma Services Adds Formulation Development Services
3. Dalton Pharma Services and ProCitius Announce a Strategic Alliance to Provide Contract Chemistry Services
4. BioRelix and Dalton Medicinal Chemistry Expand and Renew Research Agreement to Capitalize on Riboswitches
5. Dalton Pharma Services and Boehringer Ingelheim (Canada) Ltd. Announce the Renewal of their Chemistry Services Agreement
6. Bruker Daltonics Showcasing Novel Proteomics Solutions Based on Mass Spectrometry at the 7th HUPO World Congress 2008
7. PartsSource President & CEO A. Ray Dalton Named Harvard School of Business Entrepreneur of the Year
8. PartsSource President & CEO A. Ray Dalton Wins Innovation in Business Award
9. Global Regulators to Discuss Benefit-Risk Approaches of Medicinal Products at DIA Workshop
10. Medicinal products susceptible to dose dumping should be fully tested
11. Medithrive Announces the Grand Opening of Its San Francisco Medicinal Marijuana Dispensary
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
BIKAM and Dalton Medicinal Chemistry Expand and Renew Research Agreement
(Date:4/26/2017)... , ... April 26, 2017 , ... ... performance, is proud to announce that it has received 510(k) clearance from the ... MyoCycle Home and the MyoCycle Pro. , Both devices are stationary cycling systems ...
(Date:4/25/2017)... Louisville, KY (PRWEB) , ... April 25, 2017 ... ... to announce they have signed an agreement to be the preferred physical therapy ... with injuries and returning them to Derby City CrossFit as quickly and effectively ...
(Date:4/25/2017)... ... April 25, 2017 , ... As ... decision-makers are preparing for how his administration could impact the employee benefits industry. ... what changes are most likely to make it through Congress. His discussion will ...
(Date:4/25/2017)... ... April 25, 2017 , ... Lake Park Dental is now accepting new ... in Lutz, FL. With the help of this highly-effective, yet convenient system, patients ... complications, more discretion and less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara ...
(Date:4/25/2017)... RESTON, VIRGINIA (PRWEB) , ... April 25, 2017 ... ... scientists leading the way in unveiling cutting-edge birth defects research related to Zika ... recognized by the world’s premier society for this important science. , ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... April 19, 2017  Novartis today announced the ... Heart, Lung, and Blood Institute (NHLBI) of the ... of patients with treatment-naïve severe aplastic anemia (SAA) ... with eltrombopag at the initiation of and concurrently ... evaluated three sequential treatment groups, or cohorts. Cohort ...
(Date:4/18/2017)... Cogentix Medical, Inc. (NASDAQ: CGNT), a global ... and Gynecology markets with innovative and proprietary products, will ... 31, 2017 after the market close on Tuesday, May ... a conference call and webcast to discuss its financial ... at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). ...
(Date:4/18/2017)...  Astute Medical, Inc., developer of biomarkers for better ... at the 2017 National Kidney Foundation (NKF) Spring ... April 22. Physicians will present data on two biomarkers, ... for acute kidney injury (AKI) during the management of ... Elevated levels of TIMP-2 and IGFBP-7 have been ...
Breaking Medicine Technology: